SKY E&M vs Merck KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SKY E&M Co. Ltd (131100.KQ)

Merck KGaA (MRK.XETRA)

Q3 202628 Jun – 26 Sep 2026

▲2▼1

Merck KGaA advances Bio-Techne deal, raises guidance, but faces German rebate and Healthcare headwinds

Guidance raised on strong Q2 results Merck KGaA increased its 2026 outlook after Q2 organic sales grew 4.1% and EBITDA pre rose 9.3%, driven by Life Science and Electronics. This signaled confidence in continued momentum.
The guidance raise reflects better-than-expected performance and is a new positive development this quarter.
Pipeline and regulatory wins The company achieved FDA Breakthrough status for lupus drug enpatoran, updated the European Erbitux label, made fertility acquisitions, and reported positive remigromig trial results. UBS also named Merck a favoured patent-light compounder.
These pipeline and regulatory milestones are new positive catalysts that support future growth.
German rebate hike and Healthcare decline Germany's healthcare reform raised mandatory drug rebates, which Merck warned harms investment and innovation. Meanwhile, Healthcare fell 3.4% due to U.S. competition and Mavenclad's patent loss.
This is a new negative factor that pressured the Healthcare segment and overall sentiment.

August 202620 Jul – 26 Sep 2026

▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.
Guidance raise is the core earnings driver behind the stock's re-rating this period.
Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.
The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.
Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.
New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.
Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.
These show structural demand growth in two of Merck's three core businesses.

Latest20 Jul – 26 Sep 2026

▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.
Guidance raise is the core earnings driver behind the stock's re-rating this period.
Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.
The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.
Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.
New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.
Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.
These show structural demand growth in two of Merck's three core businesses.

July 202628 Jun – 29 Jul 2026

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.
This is the largest new deal and a direct driver of Merck KGaA's valuation.
UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.
Analyst positioning directly influences demand for the stock.
German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.
This is the main negative force on Merck KGaA's home-market profitability.
Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.
Pipeline and technology progress are core to Merck KGaA's long-term growth story.

28 Jun – 29 Jul 2026

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.
This is the largest new deal and a direct driver of Merck KGaA's valuation.
UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.
Analyst positioning directly influences demand for the stock.
German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.
This is the main negative force on Merck KGaA's home-market profitability.
Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.
Pipeline and technology progress are core to Merck KGaA's long-term growth story.

Q2 202623 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

June 202623 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

23 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.